ARCpointARCPF -56.33% EBITDA Margin % is 20.13% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, ARCpoint ranks worse than 83.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ARCpoint's EBITDA for the
three
months ended in Dec. 2025 was $0.03 Mil. ARCpoint's Revenue for the
three
months ended in Dec. 2025 was $0.15 Mil. Therefore, ARCpoint's EBITDA margin for the quarter that ended in Dec. 2025 was 20.13%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ARCpoint EBITDA Margin % Related Terms
ARCpoint EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ARCpoint's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCPF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, ARCpoint's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARCpoint EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ARCpoint's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ARCpoint's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCpoint (ARCPF) has a EBITDA Margin % of 20.13% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ARCpoint and its competitors. According to the industry distribution chart, ARCpoint ranks #171 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is ARCpoint's EBITDA Margin % too high?
ARCpoint's current EBITDA Margin % is 20.13%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. ARCpoint's value of 20.13% is 287.1% above this industry median. Based on the distribution chart, ARCpoint ranks #171 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ARCpoint's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ARCpoint ranks #171 out of 204 companies for EBITDA Margin %. This places ARCpoint in the lower half of its industry. The industry median EBITDA Margin % is 5.20. ARCpoint's value of 20.13% is 287.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ARCpoint's current EBITDA Margin % of 20.13% is 287.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ARCpoint and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ARCpoint's current EBITDA Margin % is 20.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARCpoint stock overvalued right now?
Based on GuruFocus' analysis, ARCpoint (ARCPF) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current EBITDA Margin % is 20.13% and 287.1% above the Medical Diagnostics & Research industry median of 5.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ARCpoint (ARCPF), the current EBITDA Margin % is 20.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARCpoint Inc is a U.S-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing, corporate wellness programs, and employment and background screening, among other services. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing, and physician services for ARCpoint franchise labs and other clients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCPF has been successfully added to your 